Certara, Inc. (CERT)

NASDAQ • Healthcare

$7.55

+$0.12 (+1.8%)

Market closed

Last close at September 11, 2026 at 20:00 UTC

Open$7.51

Day Range$7.39 - $7.57

Avg. Volume (3M)2.1M

Market Cap$1.1B

52 Week Range

$4.45$13.88

Next EarningsIn 53 daysNov 5, 2026

Metrics Over Time

Where the Money Goes

Q2 2026

Revenueeverything earned$93.2M100%

Gross Profitminus cost of goods$58.1M62%

In plain terms: out of every $100 in revenue, Certara, Inc. currently loses $59.

Fundamentals & Financials

Revenue (TTM)

$408.4M

Net Income (TTM)

-$68.4M

EPS (TTM)

-$0.44

ROA (TTM)

-4.89%

Current Ratio

2.55

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

-30.0%Q3 2025$0.07

+27.3%Q4 2025$0.14

-18.2%Q1 2026$0.09

-18.2%Q2 2026$0.09

-10.4%Q3 2026$0.08

Nov 5

in 53 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

View full earnings history

About Certara, Inc.

Certara, Inc. (NASDAQ: CERT) provides drug-development software and technology-enabled services for healthcare organizations, centered on biosimulation across the development lifecycle. The company operates in medical and healthcare information services and generated $418.8 million of revenue in FY2025, serving biopharmaceutical, academic, and government customers through software and services tied to research, regulatory work, and market access.

Name

Certara, Inc.

CEO

Jon Resnick

Website

www.certara.com

Industry

Healthcare

Year Founded

2008

Employees

1,546

Today's Snapshot

AI-generated

CERT closed 1.8% above yesterday's close, while its sector was flat.

Trading Volume

Below 10d avg (1.9M)

1.3M

vs S&P 500 Today

Outperforming Market

+0.82%

Updated: September 11, 2026 at 20:19 UTC

Technical Indicators

2 Buy1 Neutral5 Sell

CERT is trading near 7.55 with a clearly bearish short-term footprint: most short and medium moving averages lie above the market and momentum indicators are weak, including a steeply negative CCI and a small negative MACD. RSI sits in the lower range and ADX indicates little trend strength, while on‑balance volume is declining. Volatility is moderate with ATR about 4%, and the pivot level is close below the current price. Technical takeaway: Sell — short-to-intermediate momentum and volume favor the downside.

All signals